Trials / Completed
CompletedNCT00881179
To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions
A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA) | |
| DRUG | Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA) |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2002-06-01
- Completion
- 2002-06-01
- First posted
- 2009-04-15
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00881179. Inclusion in this directory is not an endorsement.